Pharmacokinetics of benzodiazepine hypnotics

David J. Greenblatt, Marcia Divoll, Darrell R. Abernethy, Ann Locniskar, Richard I. Shader

Research output: Contribution to journalArticle

Abstract

Three benzodiazepine derivatives are currently indicated specifically for the treatment of insomnia in the United States. Flurazepam is biotransformed to at least two rapidly appearing and rapidly eliminated intermediate metabolites which probably contribute to sleep induction. The final metabolite, desalkylflurazepam, appears slowly, but has a long half-life ranging from 40 to 150 h. This metabolite accumulates extensively during multiple dosage. Temazepam is a slowly absorbed drug and has an intermediate half-life in the range of 10-20 h. Triazolam has an intermediate absorption rate, but is rapidly eliminated (half-life 1.5-5 h) making it essentially non-accumulating. Understanding of the pharmacokinetics of benzodiazepine hypnotics can contribute to understanding of their clinical properties.

Original languageEnglish (US)
Pages (from-to)70-75
Number of pages6
JournalPharmacology
Volume27
DOIs
StatePublished - Jan 1 1983

Keywords

  • Benzodiazepines
  • Flurazepam
  • Hypnotics
  • Pharmacokinetics
  • Temazepam
  • Triazolam

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Pharmacokinetics of benzodiazepine hypnotics'. Together they form a unique fingerprint.

  • Cite this

    Greenblatt, D. J., Divoll, M., Abernethy, D. R., Locniskar, A., & Shader, R. I. (1983). Pharmacokinetics of benzodiazepine hypnotics. Pharmacology, 27, 70-75. https://doi.org/10.1159/000137913